Lineage Cell Therapeutics, Inc. (LCTX) Operating margin 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) operating margin by fiscal year — reported operating income divided by reported revenue.
-251.6%FY2025 · since FY2016: -995.6% → -251.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -251.6% | -25.5 pp |
| FY2024 | -226.1% | +50.4 pp |
| FY2023 | -276.5% | -123.3 pp |
| FY2022 | -153.2% | +980.5 pp |
| FY2021 | -1133.6% | +314.7 pp |
| FY2020 | -1448.4% | -342.4 pp |
| FY2019 | -1106.0% | -268.1 pp |
| FY2018 | -837.9% | +287.1 pp |
| FY2017 | -1125.0% | -129.4 pp |
| FY2016 | -995.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →